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One of the major effects of aging on the cardiovascular (CV) system 
is the decreased compliance (elasticity) of the arterial system, ie, in‐
creased arterial stiffness, with a consequential rise in pulse wave ve‐
locity (PWV). This increases left ventricular afterload along with the 
systolic blood pressure, promotes left ventricular hypertrophy, and 
reduces myocardial blood supply resulting in myocardial ischemia. 
Therefore, measuring the degree of arterial stiffness, PWV becomes 
a surrogate marker of unfavorable CV outcomes, connecting the tra‐
ditional cardiovascular continuum with the novel concept of vascu‐
lar aging.1 Additionally, the predictive value of aortic PWV for future 
CV events and all‐cause mortality is higher in subjects with a higher 
baseline CV risk (hypertension, renal disease, coronary artery disease) 
compared to the general population.2 Moreover, an increased pulse 
pressure, which is reflective of aortic stiffness, is an important risk fac‐
tor for incident atrial fibrillation (AF) in the general population.3 The 
incidence of AF, with its deleterious impact on CV outcomes, exponen‐
tially rises with age together with age‐related increases in aortic stiff‐
ness.4,5 Hence, the 2013 European Society of Hypertension/European 
Society of Cardiology guidelines for the management of arterial hyper‐
tension recommended the measurement of aortic PWV for evaluation 
of subclinical organ damage in hypertensive patients, with a suggested 
cutoff value of 10 m/s (recommendation Class IIa, Level of Evidence B).6
In this issue of the journal, Silva and colleagues7 investigated 
data (1192 participants) on arterial stiffness in the mostly hyper‐
tensive (81%) elderly (inclusion criterion was ≥ 60 years, mean age 
69.2 years) multiethnic population of a large urban area in Brazil. 
These normative values from Brazil are interesting in that they pro‐
vide information from an intriguing ethnic group, as Latin American 
countries are traditionally characterized by a high degree of mis‐
cegenation between whites and blacks making the assessment of 
ethnic differences very challenging. Although nonblack patients 
represented the majority of the studied population, no significant 
differences regarding PWV were observed between the ethnic 
categories.
Of note, studies from different European centers (PWVs were 
9.3 and 11.1 m/s in normotensives and hypertensive elderly patients, 
respectively) and from Chinese hypertensive patients (PWV was 
12.5 m/s) have reported higher PWV values than those found in this 
Latin American study (PWVs were 9.1 and 9.4 m/s in controlled and 
uncontrolled elderly hypertensives, respectively).8,9
In this elderly hypertensive population, the PWV values in‐
creased with age and reached a plateau at the age of 75 years. 
Controlled hypertensive patients exhibited PWV values that were 
similar to normotensives and significantly lower (P = 0.04, adjusted 
for age, gender, and mean arterial pressure) than those of the un‐
controlled hypertensive population, suggesting that effective an‐
tihypertensive treatment can delay or maybe even reverse arterial 
stiffening. Future studies will show the potential role of PWV as an 
independent treatment target, ie, the role of PWV as a potential sur‐
rogate end‐point of unfavorable CV outcomes.
Notably, the renin‐angiotensin system inhibitors proved to be supe‐
rior to all other antihypertensive drugs in reducing arterial stiffness.10 
This is most likely due to abolishing the pro‐fibrotic action of angioten‐
sin II, although this was not shown in the aforementioned study.
In conclusion, aortic PWV integrates the long‐term effects of the 
traditional risk factors together with the individual’s genetic back‐
ground on the arterial wall and serves as a barometer of vascular 
aging with greater prognostic impact in populations with a higher 
baseline CV risk.
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